Hemostemix Inc. (CVE:HEM – Get Free Report) shares dropped 22.9% during trading on Friday . The company traded as low as C$0.18 and last traded at C$0.19. Approximately 504,239 shares changed hands during trading, a decline of 5% from the average daily volume of 530,580 shares. The stock had previously closed at C$0.24.
Hemostemix Stock Performance
The stock has a 50 day simple moving average of C$0.19 and a 200 day simple moving average of C$0.11. The company has a market cap of C$26.96 million, a price-to-earnings ratio of -5.39 and a beta of 0.20. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- What is the Dow Jones Industrial Average (DJIA)?
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
- 3 Fintech Stocks With Good 2021 Prospects
- Cisco Roars Back: Is the Tech Giant Reborn?
- How to Choose Top Rated Stocks
- Albemarle’s Earnings Are In—Is the Stock a Buy Now?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
